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One of the earliest events in the pathogenesis of systemic sclerosis (SSc) is microvas-
culature damage with intimal hyperplasia and accumulation of cells expressing PDGF 
receptor. Stimulatory autoantibodies targeting PDGF receptor have been detected in 
SSc patients and demonstrated to induce fibrosis in vivo and convert in vitro normal 
fibroblasts into SSc-like cells. Since there is no evidence of the role of anti-PDGF receptor 
autoantibodies in the pathogenesis of SSc vascular lesions, we investigated the biologic 
effect of agonistic anti-PDGF receptor autoantibodies from SSc patients on human pul-
monary artery smooth muscle cells and the signaling pathways involved. The synthetic 
(proliferation, migration, and type I collagen gene α1 chain expression) and contractile 
(smooth muscle-myosin heavy chain and smooth muscle-calponin expression) profiles 
of human pulmonary artery smooth muscle cells were assessed in vitro after incubation 
with SSc anti-PDGF receptors stimulatory autoantibodies. The role of reactive oxygen 
species, NOX isoforms, and mammalian target of rapamycin (mTOR) was investigated. 
Human pulmonary artery smooth muscle cells acquired a synthetic phenotype charac-
terized by higher growth rate, migratory activity, gene expression of type I collagen α1 
chain, and less expression of markers characteristic of the contractile phenotype such 
as smooth muscle-myosin heavy chain and smooth muscle-calponin when stimulated 
with PDGF and autoantibodies against PDGF receptor, but not with normal IgG. This 
phenotypic profile is mediated by increased generation of reactive oxygen species and 
expression of NOX4 and mTORC1. Our data indicate that agonistic anti-PDGF receptor 
autoantibodies may contribute to the pathogenesis of SSc intimal hyperplasia.
Keywords: systemic sclerosis, autoantibodies, vascular smooth muscle cells, platelet-derived growth factor, 
synthetic phenotype
TaBle 1 | clinical characteristics of systemic sclerosis patients (n = 11).
Male/female 2/9
Mean age, years (range) 56 (43–73)
Mean modified Rodnan skin score (range) 11 (4–30)
Subset ISSc/dSSc 5/6
Median disease duration, years (range) 7 (2–21)
Antitopoisomerase I-positive patients 6
Anticentromere-positive patients 2
ANA-positive patients 3
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inTrODUcTiOn
Systemic sclerosis (SSc; scleroderma) is a multiorgan disorder 
characterized by microvasculature damage, circulating autoan-
tibodies, and fibroblast activation leading to fibrosis of the skin 
and visceral organs (1–3).
Vascular involvement is an early and very likely primary 
event in the pathogenesis of scleroderma, precedes fibrosis, and 
is characterized by endothelial cell (EC) injury and dysfunction, 
altered capillary permeability, increased expression of adhe-
sion molecules, abnormal secretion of vasoactive mediators, 
and activation of platelets and fibrinolytic pathways (4–7). 
Microvascular injury and damage lead to vascular remodeling 
with striking intimal hyperplasia (also called neointima) due 
to increase in cell number and extracellular matrix and marked 
luminal narrowing (7, 8). The process culminates in rarefaction 
of blood vessels on nailfold capillaroscopy of SSc patients with 
late-stage disease (9). Loss of microvasculature is associated with 
tissue hypoxia, which induces strong expression of VEGF and its 
receptors (10–12).
The source of the intimal cells in scleroderma vasculopathy 
is a matter of debate. Medial smooth muscle cells, pericytes, 
circulating fibrocytes, ECs, adventitial fibroblasts, and adventi-
tial stem cells have all been held responsible (13). Furthermore, 
the exact cause of vascular injury in SSc is unknown, and it 
may include reactive oxygen species (ROS)-mediated damage, 
viral agents, anti-EC antibodies, ischemia–reperfusion events, 
cytotoxic T-lymphocytes, and antibody-dependent cellular 
cytotoxicity [see for review Ref. (14)]. A further mechanisms has 
been reported by Riemekasten et al. who detected serum autoan-
tibodies against angiotensin II type I receptor and endothelin-1 
type 1 receptor, which induced extracellular signal-regulated 
kinase 1/2 (ERK 1/2) phosphorylation and increased TGF-β 
gene expression in ECs and were associated with severe disease 
manifestations (15).
While over the years much attention has been devoted to EC 
injury in scleroderma, oddly enough no in vitro studies focused 
on smooth muscle cells that are rich in PDGF receptors (PDGFR) 
(16), a key signaling molecule in the pathogenesis of SSc fibrosis. 
High levels of PDGF and PDGF receptor β (PDGFR β) have 
been found in skin lesions from patients with scleroderma (17, 
18) and may contribute to the differentiation of perivascular 
pericytes into vascular smooth muscle cells, fibroblasts, and 
myofibroblasts (19). The beneficial effects of selective inhibitors 
of PDGF signaling on dermal fibrosis (20, 21) and lung fibrosis 
(22) further indicate the importance of PDGF in scleroderma. 
Finally, the relevance of PDGFR has been further emphasized 
by the high prevalence of anti-PDGFRα autoantibodies in SSc 
sera (23, 24).
Anti-PDGFRα autoantibodies play a role in the pathogenesis 
of scleroderma since they convert in vitro normal fibroblasts into 
SSc-like cells via the ROS, RAS, and ERK 1/2 pathway (23–26) 
and are capable to induce fibrosis in  vivo (27). No report has, 
however, described their effect on human smooth muscle cells, 
and since a better understanding of the molecular mechanisms 
involved in scleroderma vascular events could help to prevent 
severe complications such as digital ulcers, pulmonary hyperten-
sion, and renal crisis, which are responsible for a substantially 
reduced survival and impaired quality of life (28–30), we decided 
to investigate the biological effects of SSc agonistic anti-PDGFR 
autoantibodies on human pulmonary artery smooth muscle cells 
(HPASMC) in vitro.
MaTerials anD MeThODs
Patients and Biological samples
Serum samples were obtained from 11 SSc patients (2 were male 
and 9 were female) with median age of 56 years (range, 43–73 
years), and median disease duration (defined as the time from the 
onset of the first non-Raynaud’s phenomenon clinical manifesta-
tion) was 7 years (2–21). Diagnosis was made following the ACR/
EULAR preliminary criteria for the classification of SSc (31). Five 
patients had limited cutaneous SSc and six diffuse cutaneous SSc 
according to LeRoy et al. (32). Six patients were antitopoisomer-
ase I positive; two patients were anticentromere positive, and 
three were ANA positive but lacked specific SSc autoantibodies. 
In the whole group, median PAPs detected by echocardiography 
was 30  mmHg (range, 28.5–36.5 mmHg) (Table  1). The study 
was approved by the local ethic committee. A written informed 
consent was obtained from all patients. At the time of the inves-
tigation, patients who had never been on immunosuppressive 
therapy had not received any treatment for the previous 6 weeks. 
Control sera were obtained from 10 age-, sex-, and race-matched 
normal, non-smoking, healthy volunteers. All subjects provided 
informed consent and the study protocol was approved by the 
Institutional Ethics Committee of Università Politecnica delle 
Marche.
antibody Purification
Immunoglobulins were purified from serum using gravity flow 
column packed with protein A/G agarose following manufacturer 
instruction (Pierce). Concentrations of all samples were calculated 
based on absorbance at 280  nm. The eluted IgG fractions that 
contain the highest absorbance were subjected to buffer exchange 
with PBS using desalting column, a size-exclusion chromatogra-
phy with an average molecular weight exclusion limit of 5 KDa 
(Pierce). Purity of IgG preparations was checked by Coomassie 
blue staining, and PDGF and TGF-β contaminations were ruled 
out by immunoblotting with biotinylated anti-human PDGF-BB 
and anti-human TGF-β antibodies (Abcam), respectively, with 
detection limit of 0.1 ng cytokine/200 μg IgG.
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human Monoclonal anti-PDgFrα 
autoantibodies
Agonistic (VHPAM-Vκ16F4) and non-agonistic (VHPAM-
Vκ13B8) human monoclonal autoantibodies targeting 
PDGFRα were generated from SSc memory B cells as already 
described (24).
cell cultures
Human pulmonary artery smooth muscle cells (HPASMC) were 
purchased from Lonza and maintained in Medium 231 supple-
mented with smooth muscle growth medium (SMGM) and 100 
U/ml penicillin/streptomycin (all from Life Technologies). Cells 
between passages 3 and 9 were used in all experiments performed 
after 24 h of starvation (0.1% SMGM).
Total IgGs were isolated from each patient and control and 
were singly tested in triplicate. The same conditions were applied 
to human monoclonal antibodies. Each experiment was per-
formed at least three times. Means of all experiments are shown.
rOs Detection
Relative changes in intracellular ROS were monitored using the 
fluorescent probe 2′, 7′-dichlorfluorescein-diacetate (DCFH-DA; 
Life Technologies). Cells were plated at 2.5 ×  105/ml and then 
incubated with scleroderma (SSc IgG) or normal subjects IgG (N 
IgG) (200 µg/ml), PDGF (15 ng/ml), or human monoclonal anti-
PDGFRα autoantibodies (10 µg/ml) for 15 min and then stained 
with 10 µM DCFH-DA (Life Technologies) for 10 min at 37°C. 
Fluorescence was read using a plate reader fluorimeter (Victor 2, 
Perkin Elmer).
For confocal microscopy experiments, cells were seeded on 
coverslides and treated as described earlier. Cells were loaded 
with 10 µM DCFH-DA for 30 min, washed with PBS, and then 
visualized on a confocal microscope Eclipse C1 (Nikon). Data 
were analyzed by ImageJ software.
The intracellular content of ROS was also measured at a single-
cell level by flow cytometry (FACS, Becton Dickinson). Briefly, 
cells were detached by trypsin, washed with PBS, and incubated 
with 5 µM DCFH-DA for 20 min at 37°C. Cells were then washed 
and resuspended in 1  ml PBS. For each sample, 10,000 events 
were collected, and intracellular ROS formation was detected as a 
result of oxidation of DCFH-DA at a wavelength of 520 nm. Data 
analysis was carried out using the WinMDI software.
Where indicated, the inhibitor of flavoprotein-dependent 
oxidases diphenyleneiodonium (DPI; 10  µM, Calbiochem), a 
general ROS inhibitor N-acetyl-cysteine (NAC; 10 mM, Sigma), 
and the PDGFR chemical inhibitor AG1296 (2 µM, Calbiochem) 
were added 1 h before stimulation.
Proliferation assay
Cell proliferation was determined by 5-bromo-2′-deoxyuridine 
(BrdU) incorporation assay (Roche). Briefly, HPASMC were 
seeded in 96-well pates at a density of 2.5 × 105 cells/ml and then 
treated with SSc IgG or N IgG (200 µg/ml), PDGF (15 ng/ml), 
or human monoclonal anti-PDGFRα autoantibodies (10 µg/ml) 
for 48 h. Cells were pulsed for 6 h with BrdU, and plates were 
analyzed in a plate reader at 450 nm (Victor 2, PerkinElmer).
Migration assay
Migration was studied by the wound scratch assay (33). Briefly, 
the cell monolayer was scraped by a straight line to create a 
“scratch” with a pipette tip. Cells were incubated for 24 h with 
SSc IgG, N IgG (200 µg/ml), PDGF (15 ng/ml), or human mono-
clonal anti-PDGFRα autoantibodies (10 µg/ml) in the presence 
or absence of inhibitors. Mitomycin was added to inhibit cell 
proliferation. Unstimulated cells were used as negative controls. 
The percentage of cells repopulating the scratch wound was 
assessed after 24 h.
reverse Transcriptase Polymerase  
chain reaction
Total RNA was isolated from HPASMC with Pure Link RNA 
Minikit (Life Technologies) and reverse transcribed using 
IScript cDNA Synthesis Kit (Bio-Rad Laboratories) according 
to the instructions of the manufacturer. Gene expression was 
quantified by SYBR Green real-time PCR in a iCycler iQ™ real-
time PCR Detection System (Bio-Rad). Specific primer pairs 
for each gene were designed with the Universal ProbeLibrary 
Assay Design Centre by Roche Applied Science and were as fol-
lows: NOX1 5′-CTGTTTGTGGATGCCTTCCT-3′ (forward), 
5′-TGTGGAAGGTGAGG-TTGTGA-3′ (reverse); NOX2 5′-TC 
ACTTCCTCCACCAAAACC-3′ (forward), 5′GGGATTGGGC 
ATTCCTTTAT-3′ (reverse); NOX4 5′-CTTCCGTTGGTTTG 
CAGATT-3′ (forward), 5′-GAATTGGGCCACAACAGA-3′ 
(reverse); type I collagen α1 chain (COL1A1) 5′-AGGGCCA 
AGACGAAGACATC-3′ (forward), 5′-AGATCACGTCATCGC 
ACAACA-3′ (reverse); smooth muscle-myosin heavy chain 
(SM-MHC) 5′-CAGGCGTTCCGCCAACGCTA-3′ (forward), 
5′-TCCCGTCCATGAAGCCTTTGG-3′ (reverse); smooth mus-
cle-calponin (sm-calponin) 5′-TTTTGAGGCCAACGACCT 
GT-3′ (forward), 5′-TCCTTTCGTCTTCGCCATG-3′ (reverse); 
and GAPDH 5′-TGCACCACCAACTGCTTAGC-3′ (forward), 
5′-TGGGATTTCCATTGATGA-CAAGC-3′ (reverse).
GAPDH was used to test the quality of cDNA and as a house 
keeping gene in real-time PCR. The threshold cycle (Ct) was used 
to detect the increase in the signal associated with an exponential 
growth of PCR product during the log-linear phase. The relative 
expression was calculated using the following formula: 2−ΔΔCt. 
The ΔCt validation experiments showed similar amplification 
efficiency for all templates used (difference between linear slopes 
for all templates less than 0.1).
immunoblotting
Cells were lysed in RIPA buffer [1× PBS, 1% non-idet P-40, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 
2 mM sodium orthovanadate] supplemented with a cocktail of 
protease inhibitors (Sigma). Proteins were separated on 4–12% 
gradient SDS–polyacrylamide gels, transferred onto nitrocel-
lulose membranes, and immunoblotted with antibodies against 
NOX4, β-actin (Santa Cruz Biotechnology), and phospho mTOR 
and mTOR (Cell Signalling). Signals were detected by chemilu-
minescence (Pierce). Densitometric analysis was performed with 
Quantity One software (BioRad). Where indicated rapamycin 
(10 nM) was added 48 h before stimulation.
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nOX4 intracellular expression
For intracellular staining assay, HPASMC were treated with SSc 
IgG or N IgG (200 µg/ml) and PDGF (15 ng/ml) for 24 h and then 
permeabilized with Cyto Fix/Perm (Becton Dickinson). Cells 
were detached by trypsin, washed with PBS, and incubated with 
antibody against NOX4 (AbCam) for 24  h at 37°C. Cells were 
then washed and incubated with FITC-conjugated secondary 
antibody and resuspended in 1 ml PBS. For each sample, 10,000 
events were collected. Data analysis was carried out using the 
WinMDI software.
small interfering rna (sirna) 
experiments
Nox4 was silenced using siRNA oligoribonucleotides (Qiagen) 
using Lipofectamine™ 2000 reagent (Life Technologies) 
following the manufacturer’s instructions. Briefly, 10  µM 
NOX4 siRNA or scrambled oligos and Lipofectamine 2000 
were mixed in serum-free Medium 231 without antibiotics 
and then added to the cells. Medium was changed after 4 h. 
Gene silencing and ROS production were monitored 72 h after 
transfection.
statistical analysis
Statistical analysis was performed using GraphPad Prism version 
4.0 by two-tailed Student’s t-test. P values less than 0.05 were 
considered significant.
resUlTs
agonistic anti-PDgFrα receptor 
autoantibodies from ssc Patients induce 
increased rOs generation in hPasMc
Since the pathogenesis of scleroderma is characterized by an 
abnormal generation of ROS [for review, see Ref. (34)] and 
several lines of evidence implicate oxidative stress in the patho-
genesis of PAH (35), we exploited our previous demonstration 
that agonistic anti-PDGFRα autoantibodies isolated from SSc 
sera induce an abnormal generation of ROS in normal fibro-
blasts via NOX (23, 24, 36). Hence, HPASMC were stimulated 
in vitro with IgG isolated from serum of distinct scleroderma 
patients (SSc IgG; n = 11) or distinct normal controls (N IgG; 
n  =  10) (200  µg/ml, 15  min) and then incubated with the 
peroxide-sensitive fluorophore DCHF-DA. Confocal micros-
copy (Figure 1A), plate reader fluorimeter (Figure 1B), or FACS 
analysis (Figure  1C) showed that the levels of ROS, induced 
by PDGF and SSc IgG, were higher than the levels obtained 
in unstimulated cells (p <  0.05) and were inhibited by prein-
cubating cells with PDGFR tyrosine kinase inhibitor AG 1296 
(2 µM, 1 h) (p < 0.05), indicating that ROS production occurred 
through PDGFRα. The amount of ROS generated by N IgG was 
not significantly different from that obtained in unstimulated 
cells (Figures 1A–C).
Systemic sclerosis IgGs contain a multitude of SSc disease-
specific and non-specific antibodies, including agonistic 
autoantibodies against angiotensin II receptor type 1 and the 
endothelin receptor type A (37). Thus, to demonstrate that the 
findings reported above are related to stimulatory antibodies 
targeting PDGFRα, HPASMC were exposed to combinatorial 
human monoclonal anti-PDGFRα autoantibody VHPAM-
Vκ16F4 (10  µg/ml), which binds and stimulate the PDGFRα 
in  vitro, and to antibody VHPAM-Vκ13B8 (10  µg/ml), which 
binds but does not stimulate the receptor in vitro (24). Figure 1D 
shows that the agonistic antibody VHPAM-VK16F4-stimulated 
cells produced significantly larger amount of ROS compared to 
unstimulated cells and VHPAM-VK13B8-treated HPASMC. No 
difference was observed between VHPAM-VK13B8-treated and 
unstimulated cells.
enhanced Migration and Proliferation of 
hPasMc by ssc igg through PDgFr
The in vitro scratch assay was used to study the effect of SSc IgG 
on HPASMC migration (33). Incubation with PDGF (15 ng/ml) 
or SSc IgG (200 µg/ml) for 24 h enhanced migratory ability of 
HPASMC compared to cells not stimulated used as controls (50 
and 45%, respectively, over control cells, p < 0.05) (Figure 2A). 
Migration after N IgG was not statistically different from that 
of unstimulated HPSMC. The addition of AG1296 (2 µM, 1 h) 
significantly reduced PDGF- or SSc IgG-induced migration 
(p < 0.05). AG1296-treated cells did not differ from unstimulated 
or N IgG-treated cells (p = n.s.) (Figure 2A).
Agonistic VHPAM-VK16F4 (10 µg/ml) significantly stimulated 
HPSMC migration when compared to unstimulated cells and 
VHPAM-VK13B8-treated cells (60 and 62%, respectively; p < 0.05) 
(Figure 2A). No difference was detected between unstimulated 
and VHPAM-VK13B8-treated cells (p = n.s.) (Figure 2A).
HPASMC were incubated with PDGF (15  ng/ml) or IgG 
isolated from serum of distinct scleroderma patients (SSc IgG; 
n = 11) or normal controls (N IgG; n = 10) (200 µg/ml) for 48 h, 
and cell proliferation was determined by monitoring BrdU incor-
poration for 6 h. SSc IgG and PDGF significantly increased the 
number of BrdU-positive cells compared to unstimulated cells 
(1.8- and 1.58-fold, respectively; p < 0.05). This effect was reverted 
by incubating HPSMC with AG1296 (2 µM, 1 h) (Figure 2B). No 
difference was demonstrated between unstimulated cells and N 
IgG-treated cells. These findings were confirmed when cells were 
exposed to VHPAM-VK16F4 and proliferation compared to that 
obtained with VHPAM-VK13B8 (Figure 2B).
To determine whether SSc IgG contributed to establish a 
phenotypic modulation of HPASMC cells favoring a transition 
from contractile to synthetic state, we detected the expression of 
transcripts of COL1A1 and smooth muscle cell-specific contrac-
tile markers, SM-MHC, and SM-calponin mRNA (38). PDGF 
and SSc IgG increased COL1A1 gene expression (2.8 ± 0.7- and 
2.4 ± 0.2-fold, respectively, when compared to unstimulated cells; 
p < 0.05) and decreased SM-MHC expression (0.46 ± 0.2- and 
0.5  ±  0.1-fold, respectively, when compared to unstimulated 
cells; p < 0.05) and SM-calponin transcription (0.35 ± 016- and 
0.4 ±  0.16-fold, respectively, when compared to unstimulated 
cells, respectively; p < 0.05) consistent with a synthetic phenotype 
(Figure 2C). Cells incubated with N IgG showed the same levels 
of transcripts of unstimulated cells. Experiments performed in 
the presence of AG1296 confirmed the role of PDGFR as a pri-
mary target of SSc IgG. All these findings are consistent with the 
FigUre 1 | agonistic anti-PDgF receptor autoantibodies from systemic sclerosis (ssc) patients induce increased reactive oxygen species (rOs) 
generation in hPasMc. HPASMC were exposed to PDGF (15 ng/ml) or IgG isolated from each SSc patients (SSc IgG; n = 11; 200 µg/ml) or normal controls (N 
IgG; n = 10; 200 µg/ml) for 15 min in the presence or absence of AG1296 (2 µM) that was added 1 h before stimulation with Ig. Unstimulated cells were used as a 
control (C). (a) Generation of intracellular ROS was evaluated by fluorescence microscopy using DCHF-DA as a oxidative probe. Representative images of three 
independent experiments are shown (upper panel). Scale bar = 100 µm. The fluorescence was quantified by ImageJ software (lower panel). The IgG from each 
subject was tested. Data are presented as mean ± SD of three independent experiments. *p < 0.05. (B) Intracellular ROS production measured by plate reader 
fluorimeter. The IgG from each subject was tested in triplicate. Data are presented as mean ± SD of three independent experiments. *p < 0.05. (c) ROS production 
of untreated cells (C) (black line), SSc IgG-treated cells (green line), N IgG-treated cells (red line), and PDGF-treated cells (blue line) by FACS analysis. A 
representative histogram of three independent experiments is shown. (D) HPASMC were stimulated for 15 min with PDGF (15 ng/ml), SSc IgG (200 µg/ml), and the 
agonistic (VHPAM-Vκ16F4) and non-agonistic (VHPAM-Vκ13B8) human monoclonal anti-PDGFRα autoantibody (10 µg/ml each). Unstimulated cells were used as a 
control (C). ROS generation was evaluated by fluorometry. Data are presented as mean ± SD of three independent experiments. *p < 0.05.
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induction of a synthetic phenotype in HPSMC by anti-PDGFRα 
autoantibodies.
The stimulation of HPASMC by single SSc IgG occurred 
through enhanced ROS generation, since the addition of the 
generic antioxidant NAC (10  mM) and the selective NADPH 
oxidase inhibitor DPI (10  µM) for 1  h before stimulation 
significantly prevented cell migration and proliferation induced 
by PDGF (15 ng/ml) and SSc IgG (200 µg/ml; n = 11) (p < 0.05) 
(Figures 3A,B). Moreover, the upregulation of COL1A1 and the 
reduction of mRNA transcript for SM-MHC and SM-calponin 
induced by PDGF and SSc IgG were reverted by the addition of 
NAC and DPI (Figure 3C).
FigUre 2 | Biological effects induced by systemic sclerosis (ssc) iggs are mediated by PDgF receptor α (PDgFrα). (a) Migration was analyzed by the 
wound healing scratch test. Cells were scraped and stimulated with PDGF (15 ng/ml), distinct SSc IgG (200 µg/ml, n = 11), or distinct N IgG (200 µg/ml, n = 10) in 
the presence or absence of AG1296 or with agonistic (VHPAM-Vκ16F4) and non-agonistic (VHPAM-Vκ13B8) human monoclonal anti-PDGFRα autoantibody. After 
24 h, the gap size was measured and expressed as a percentage of the original wound. The IgG from each subject was tested in triplicate. Data are presented as 
mean ± SD of three independent experiments. *p < 0.05. (B) HPASMC treated with PDGF (15 ng/ml), single-tested SSc IgG (200 µg/ml; n = 11), or N IgG (200 µg/
ml; n = 10) or with the human monoclonal anti-PDGFRα autoantibody VHPAM-Vk16F4 and VHPAM-Vκ13B8 for 48 h in the presence or the absence of AG1296 
(2 µM). Proliferation was determined by 5-bromo-2′-deoxyuridine assay and expressed as fold increase over controls. The IgG from each subject were tested in 
triplicate. Data are presented as mean ± SD of five independent experiments. *p < 0.05. (c) HPASMC were treated with AG1296 (2 µM) for 1 h and then exposed 
to PDGF (15 ng/ml), SSc IgG (200 µg/ml; n = 11), or N IgG (200 µg/ml; n = 10) for 24 h. COL1A1, smooth muscle-myosin heavy chain, and SM-calponin mRNA 
levels were measured by real-time PCR. Data are presented as mean ± SD of three independent experiments. *p < 0.05. The IgG from each subject was single 
tested.
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These results indicate that SSc IgG induce phenotypic modula-
tion and affect the rate of proliferation and migration of HPASMC 
through ROS produced by NOX activation.
enhanced expression of nOX4 by ssc  
igg in hPasMc
To identify which NOX isoforms were upregulated in stimulated 
HPASMC, we treated HPASMC with PDGF (15 ng/ml) or single 
SSc IgG (200  µg/ml; n =  11) or IgG from normal subjects (N 
IgG; n = 10) (200 µg/ml) for 24 h, and the mRNA levels of the 
different NOX isoforms were assessed by real-time PCR. After 
stimulation, NOX4 mRNA levels were significantly upregulated 
compared to unstimulated cells (8.7  ±  1.5 and 8  ±  1.6 fold, 
respectively, p <  0.05), whereas NOX2, DUOX1, and DUOX2 
were unaffected by the treatment (Figure 4A). PDGF, but not SSc 
IgG, increased NOX1 mRNA relative to control (2.9 ± 0.2-fold) 
FigUre 3 | Biological effects induced by systemic sclerosis (ssc) igg are mediated by reactive oxygen species. (a) HPASMC were scraped and 
stimulated with PDGF (15 ng/ml) or IgG isolated from each SSc patient (200 µg/ml; n = 11) and single tested in the presence or absence of N-acetyl-cysteine (NAC) 
(10 mM) or diphenyleneiodonium (DPI) (10 µM). After 24 h, the gap size was measured and expressed as a percentage of the original wound. Data are presented as 
mean ± SD of five independent experiments. *p < 0.05. (B) HPASMC treated with PDGF (15 ng/ml) and SSc IgG (200 µg/ml) for 48 h in the presence or absence of 
NAC (10 mM) or DPI (10 µM) for 1 h. Proliferation was determined by 5-bromo-2′-deoxyuridine assay and expressed as fold increase over controls. Data are 
presented as mean ± SD of five independent experiments. *p < 0.05. The IgG from each subject was single tested. (c) HPASMC were treated with NAC (10 mM) or 
DPI (10 µM) for 1 h and then exposed to PDGF (15 ng/ml) and distinct SSc IgG (200 µg/ml, n = 11) for 24 h. COL1A1, smooth muscle-myosin heavy chain, and 
SM-calponin mRNA levels were measured by real-time PCR. Data are presented as mean ± SD of three independent experiments. *p < 0.05.
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but, as demonstrated elsewhere (36), the silencing of NOX1 did 
not influence the ROS generation in these cells (data not shown).
A significant increase of NOX4 protein expression compared 
to basal conditions was observed by immunoblotting (Figure 4B; 
p < 0.05) and FACS analysis (Figure 4C; p < 0.05) after a 24-hour 
exposure to PDGF or SSc IgG, whereas no effect was observed 
after N IgG addition (200 µg/ml; n = 10).
To dissect the role of NOX4 in ROS generation after PDGF 
or SSc IgG stimulation, we silenced NOX4 using small interfer-
ing RNA (siRNA) (p <  0.05) (Figure  5A). The specific siRNA 
selectively prevented ROS generation in HPASMC stimulated 
with either 15  ng/ml PDGF or 200  µg/ml SSc IgG for 15  min 
(Figure 5B) and reverted the effects of PDGF or SSc IgG on migra-
tion and proliferation (Figures 5C,D) compared to unstimulated 
cells. Silencing of NOX4 inhibited PDGF, SSc IgG induction of 
COL1A1, and downregulation of SM-MHC and SM-calponin, 
indicating a regulatory role of NOX4 in the phenotypic modula-
tion of HPASMC (Figure 6).
mTOr Modulated the effects of ssc igg
Mammalian target of rapamycin (mTOR) is a serine/threo-
nine kinase that acts as a major activator of cell growth and 
proliferation. mTOR has also been shown to play a role in 
proliferation of vascular smooth muscle cells and when 
FigUre 4 | induction of nOX4 levels by systemic sclerosis (ssc) igg. (a) Real-time PCR analysis of NOX isoforms in HPASMC treated with PDGF (15 ng/ml) 
or IgG isolated from distinct SSc patients (200 µg/ml; n = 11) or distinct N IgG (200 µg/ml; n = 10) and single tested for 24 h. Data are presented as mean ± SD of 
three independent experiments. *p < 0.05 compared to controls. (B) Total cell lysates from HPASMC stimulated with PDGF (15 ng/ml), single SSc IgG (200 µg/ml; 
n = 5), or single N IgG (200 µg/ml; n = 5) for 24 h were analyzed by immunoblotting with a specific antibody against NOX4. β-actin was used as a control for 
normalization. One representative experiment is shown in the upper panel. Densitometric analysis from three independent experiments is reported in the lower panel. 
Data are presented as mean ± SD from three independent experiments. *p < 0.05. (c) One representative FACS analysis of NOX4 expression is shown. Cells were 
stimulated with PDGF (15 ng/ml), distinct SSc IgG (200 µg/ml; n = 11), or N IgG (200 µg/ml; n = 10); permealized; and then labeled with anti-NOX4 and secondary 
FITC-conjugated antibody.
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dysregulated has been implicated in vascular remodeling (39). 
To evaluate the role of mTOR as a possible downstream effec-
tor in stimulated HPASMC, we treated the cells with PDGF 
(15  ng/ml) or distinct SSc IgG (200  µg/ml; n =  11) for 24  h 
in the presence or absence of rapamycin (10  nM), a specific 
inhibitor of mTOR added 48 h before. Phosphorylation levels 
of mTOR were higher in samples incubated with PDGF or SSc 
IgG compared to unstimulated cells and were reverted by rapa-
mycin (Figure 7A). Moreover, the treatment with rapamycin 
significantly decreased the migration rate (Figure 7B), prolif-
eration (Figure 7C); and COL1A1 expression (Figure 7D) and 
restored the levels of SM-MHC, and SM-calponin (Figure 7D) 
in HPASMC incubated with PDGF or SSc IgG. These results 
demonstrated that mTOR is a crucial downstream signaling of 
SSc IgG effects via PDGFR.
DiscUssiOn
Vascular smooth muscle cells are highly specialized cells whose 
principal functions are contraction and regulation of blood vessel 
tone. In the mature arterial wall, they exhibit a contractile phe-
notype characterized by low rate of proliferation and expression 
of specific markers such as α-SMA, SM-MHC, and SM-calponin. 
In response to vascular injury, they can dedifferentiate into a 
proliferative and synthetic phenotype. This phenotypic switching 
contributes to intimal hyperplasia and has been linked to the 
development and progression of several vascular disease (38). 
The functional state of smooth muscle cells is controlled by a 
complex combination of local environmental cues and epigenetic 
programs that influences synthetic or contractile, as well as inter-
mediate phenotypes (40–44).
FigUre 5 | inhibition of systemic sclerosis (ssc) igg biological effects by silencing nOX4. (a) HPASMC were transfected with NOX4 or scramble siRNA for 
24 h, and NOX4 mRNA levels were analyzed by real-time PCR analysis. Data are presented as mean ± SD of three independent experiments. *p < 0.05 compared 
to cells transfected with scramble siRNA. (B) HPASMC were transfected with NOX4 siRNA or scramble siRNA for 24 h and then were stimulated with PDGF (15 ng/
ml) or distinct SSc IgG (200 µg/ml; n = 11) for 15 min. Cells were incubated with DCHF-DA, and free radical production was evaluated by fluorescence microscopy. 
Representative images of three independent experiments are shown. The fluorescence was quantified using ImageJ software (right panel). (c) HPASMC were 
transfected with NOX4 or scramble siRNA for 24 h, scraped, and stimulated with PDGF (15 ng/ml) or single SSc IgG (200 µg/ml). After 24 h, the gap size was 
measured and expressed as a percentage of the original wound. Data are presented as mean ± SD of five independent experiments. *p < 0.05. (D) Transfected 
cells with NOX4 or scramble siRNA for 24 h were treated with PDGF (15 ng/ml) or single SSc IgG (200 µg/ml; n = 11) for 48 h. Proliferation was determined by 
5-bromo-2′-deoxyuridine assay and expressed as fold increase over controls. Data are presented as mean ± SD of five independent experiments. *p < 0.05 
compared to unstimulated cells.
FigUre 6 | nOX4 silencing drives a synthetic phenotype in hPasMc. 
Transfected cells with NOX4 siRNA or scramble siRNA for 24 h were treated 
with PDGF (15 ng/ml) or systemic sclerosis IgG (200 µg/ml; n = 11) for 24 h. 
COL1A1, smooth muscle-myosin heavy chain, and SM-calponin mRNA 
levels were measured by real-time PCR. Data are presented as mean ± SD 
of three independent experiments. *p < 0.05 compared to unstimulated cells.
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In this study, we analyzed the expression of distinct functional 
markers of smooth muscle cells from human pulmonary arter-
ies exposed in  vitro to anti-PDGFR autoantibodies from SSc 
patients. In our experimental conditions, the data show that 
HPASMC acquire a synthetic phenotype characterized by higher 
growth rate, migratory activity, type I collagen gene expression, 
and minimal expression of markers characteristic of the contrac-
tile phenotype such as SM-MHC and smooth muscle-calponin. 
Thus, our findings indicate that anti-PDGFR autoantibodies may 
contribute not only to the development of SSc fibrotic lesions (23, 
26) but also to the development of the vascular features. However, 
it is important to point out that our data do not allow to establish 
whether the new phenotype is due to the conversion of normal 
contractile vascular smooth muscle cells to a less differentiate 
state or to the expansion of medial-derived multipotent vascular 
stem cells (45).
Furthermore, since none of the SSc IgGs were from patients 
with pulmonary arterial hypertension, it seems that the impact 
of anti-PDGFRα autoantibodies on vascular smooth muscle cells 
reflects a general phenomenon, that is, scleroderma vasculopa-
thy, and the association of their serum levels to specific clinical 
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features (pulmonary arterial hypertension, digital ulcers, and 
scleroderma renal crisis) must be addressed in a larger cohort of 
SSc patients.
The activation of PDGFR by SSc IgG was both selective and 
ROS dependent since the presence of AG 1296 or NAC reduced 
the proliferation and migration of HPASMC and increased the 
expression of the differentiation markers. Our data are at variance 
with the findings reported by Arts et al. (46) who demonstrated 
that in smooth muscle cells SSc IgG engaged PDGFR leading to 
the activation of the epidermal growth factor receptor through 
a PDGFR-independent pathway. Furthermore, even if SSc IgG 
induced a profibrotic change in smooth muscle cells, collagen 
gene expression and cell proliferation were not influenced. 
Finally, some crucial experimental variables such as the source 
of the cells (aortic rat versus human pulmonary smooth muscle 
cells) and the timing of stimulation may explain the difference 
between their and our data.
Reactive oxygen species are known to mediate a variety of 
intracellular process, and the identification of the sources of these 
ROS has facilitated our understanding of a number of biologi-
cal functions. Here, we demonstrated that the SSc  IgG-induced 
abnormal oxidative stress through NOX4 activation facilitated the 
synthetic phenotype of human pulmonary artery smooth muscle 
cells. Interestingly and similar to what occurs in SSc fibroblasts 
(36), SSc IgG increased the expression of NOX4, while NOX1 was 
unaffected. These findings are the exact opposite of what reported 
by Lassègue et al. (47). If this discrepancy is to be ascribed to the 
different cell line and methodology used or indicates a different 
pathophysiological role of smooth muscle cells, NOX isoforms in 
response to distinct environmental cues remain to be established. 
Furthermore, at variance with what we found in normal fibro-
blasts (36), in HPSMC, SSc IgG did not induce NOX2, suggesting 
that individual NOX enzymes may play distinct roles between cell 
types. Thus, the precise interplay of NOX2 and NOX4 in HPSMC 
following SSc IgG stimulation needs further studies.
Cell proliferation and migration are thought to be a critical 
step in fibrogenesis, and since there is a strict interplay between 
mTOR and redox-based signaling (48, 49), we addressed the con-
tribution of mTOR signaling to these phenotypes in cells exposed 
to ROS inducing stimuli.
mTOR is a serine/threonine kinase that consists of two distinct 
complexes mTORC1 and mTORC2. Growth factors, nutrients, 
FigUre 7 | Modulation of systemic sclerosis (ssc) igg effects by rapamycin. (a) HPASMC were stimulated with PDGF (15 ng/ml) or SSc IgG (200 µg/ml; 
n = 11) for 24 h in the presence or absence of rapamycin (10 nM) added 48 h before. Phosphorylation of mTOR was detected by immunoblotting, and anti-total 
mTOR antibody was used as a control for normalization. One representative experiment is shown in the upper panel. Densitometric analysis from three independent 
experiments is reported in the lower panel. Data are presented as mean ± SD. *p < 0.05. (B) Migration was analyzed through wound healing scratch test. Cells 
were scraped and stimulated with PDGF (15 ng/ml) or single SSc IgG (200 µg/ml; n = 11) in the presence or absence of rapamycin (10 nM) added 48 h before. After 
24 h, the gap size was measured and expressed as a percentage of the original wound. Data are presented as mean ± SD of five independent experiments. 
*p < 0.05. (c) HPASMC cells treated with PDGF (15 ng/ml) or single SSc IgG (200 µg/ml; n = 11) for 48 h in the presence or the absence of rapamycin (10 nM) 
added 48 h before. Proliferation was determined by 5-bromo-2′-deoxyuridine assay and expressed as fold increase over controls. Data are presented as 
mean ± SD of five independent experiments. *p < 0.05. (D) HPASMC were treated with rapamycin and then exposed to PDGF (15 ng/ml) or SSc IgG (200 µg/ml; 
n = 11) for 24 h. COL1A1, smooth muscle-myosin heavy chain, and SM-calponin mRNA levels were measured by real-time PCR. Data are presented as mean ± SD 
of three independent experiments. *p < 0.05. The IgG from each subject was single tested.
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